ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation-Reference-Cited by-同舟云学术

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

Published:2019-10 Issue: Volume:30 Page:v872-v873
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Abou-Alfa G.K.,Macarulla Mercade T.,Javle M.,Kelley R.K.,Lubner S.,Adeva J.,Cleary J.M.,Catenacci D.V.,Borad M.J.,Bridgewater J.A.,Harris W.P.,Murphy A.G.,Oh D.-Y.,Whisenant J.,Wu B.,Jiang L.,Gliser C.,Pandya S.S.,Valle J.W.,Zhu A.X.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz394.027/30082232/mdz394.027.pdf

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma;Annals of Surgical Oncology;2023-10-09

2. Genomics driven precision oncology in advanced biliary tract cancer improves survival;Neoplasia;2023-08

3. CS-iCCA, A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma: Establishment and External Validation;American Journal of Gastroenterology;2023-03-20

4. Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma;Cancers;2022-10-16

5. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN ‐01;Liver International;2022-09-15